1.2 OMIM# of the disease 130070.
1.3 Name of the analysed gene or DNA/chromosome segments B4GALT7.
OMIM# of the gene(s)
604327.
Mutational spectrum
Seven variants have been reported: six missense variants and one variant with a loss of function frameshift duplication (www.lovd.nl/ B4GALT7). The c.808C4T (p.(Arg270Cys)) variant is the most prevalent one. Six variants have occurred within the region that codes for the catalytic protein domain. The standard reference sequence indicating reported variants (ENSG00000027847) and a reference for exon numbering (ENST00000029410) can be found at http://www. ensembl.org.
Analytical methods
Sanger sequencing of the eight coding exons and flanking intronic sequences of the B4GALT7 gene (NCBI reference sequence: NM_007255.2).
Analytical validation
Sanger sequencing identifies variants in 499% of patients. Deep intronic variants, large deletions and duplications would not be detected using this approach. Novel variants with uncertain effect on function are of course possible.
1.8 Estimated frequency of the disease (Incidence at birth ('birth prevalence') or population prevalence)
If known to be variable between ethnic groups, please report): Twenty-eight genetically confirmed patients (from 25 families) have been reported. [1] [2] [3] [4] [5] The frequency and the prevalence of the disease are not known.
Diagnostic setting
Comment: Deficiency of galactosyltransferase I is an autosomal recessive disorder of O-glycosylation, first reported in 1990. 1 It is a proteoglycan defect, more specifically in the glycosaminoglycan biosynthesis. Glycosaminoglycans are attached to the serine residue of a core protein via a tetrasaccharide linkage (consisting of one xylose, two galactoses and one glucuronic acid residue). Other disorders of this 'linkeropathy' group are: XYLT1-CDG, XYLT2-CDG, B3GALT6-CDG and B3GAT3-CDG. These diseases belong to the congenital disorders of glycosylation (CDG), a large group of genetic defects in protein and lipid glycosylation. Most CDG are multisystem disorders with prominent neurological involvement. Nearly 100 CDG have been described. Subtype identification is challenging owing to the large clinical and genetic heterogeneity. There are protein glycosylation defects in N-and O-glycosylation. Most N-glycosylation disorders are recognized by serum transferrin isoelectrofocusing, whereas mucintype O-glycosylation defects are diagnosed by apo C-III isoelectrofocusing.
All or the majority of reported patients with B4GALT7-CDG showed facial dysmorphism (including triangular face, sparse scalp hair, low-set ears, widely spaced eyes, narrow mouth and abnormal dentition), mild to severe intellectual/developmental disability, short stature, hypermobility, hypotonia, hyperelastic skin, limb bowing, pes planus, advanced bone age, radio-ulnar synostosis, and radial head and phalangeal dislocation. Less frequent findings comprised delayed/ abnormal wound healing, wide forehead, flat face, proptosis, blue sclerae, glaucoma, bifid uvula, cleft palate, long slender fingers and toes, syndactyly and osteopenia. The large majority of the reported patients (22) are living on Reunion Island (in the ethnic group called 'white creoles'). These Reunion Island patients lack osteopenia and recurrent fractures. They all carry the same homozygous c.808C4T (p.(Arg270Cys)) variant (founder effect). Current screening tests for defects in O-glycosylation (mainly apo C-III isoelectrofocusing) show normal results. The diagnosis of B4GALT7-CDG is based on the clinical acumen of the physician and confirmed by mutation analysis of B4GALT7. The identification of the pathogenic variant will permit heterozygote detection in the family and prenatal diagnosis. 
TEST CHARACTERISTICS

Analytical sensitivity (proportion of positive tests if the genotype is present)
Not applicable as there is no test available.
Analytical specificity (proportion of negative tests if the genotype is not present)
See 2.1.
Clinical sensitivity (proportion of positive tests if the disease is present)
The clinical sensitivity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case. See 2.1.
Clinical specificity (proportion of negative tests if the disease is not present)
The clinical specificity can be dependent on variable factors such as age or family history. In such cases, a general statement should be given, even if a quantification can only be made case by case. See 2.1.
Positive clinical predictive value (life-time risk of developing the disease if the test is positive)
Negative clinical predictive value (probability of not developing the disease if the test is negative)
Assume an increased risk based on family history for a non-affected person. Allelic and locus heterogeneity may need to be considered.
Index case in that family had been tested: See 2.1. Index case in that family had not been tested: See 2.1.
CLINICAL UTILITY
3.1 (Differential) diagnostics: The tested person is clinically affected (To be answered if in 1.9 'A' was marked). 
